OpenEvidence × Wiley
Wiley announced a strategic partnership to license its trusted scientific and medical content to OpenEvidence, a medical AI platform used by physicians at the point of care. [43, 44] The licensed portfolio includes the influential Cochrane Database of Systematic Reviews, Cochrane Clinical Answers, and over 400 Wiley journals and books across key medical specialties. [43, 44] The financial terms of the deal were not disclosed, but it was named as a key driver of Wiley's $49 million in AI-related revenue for its 2026 fiscal year. [55]
The asset
A license to a portfolio of scientific and medical content, including the Cochrane Database of Systematic Reviews and over 400 journals and books, to be integrated into a medical AI platform.
- 400 journals and books
The record
- Seller status
- Going concern
- Sector
- scholarly_publishing
- Modalities
- text
- Jurisdiction
- US
What it means if you hold data
This deal illustrates the critical importance of grounding clinical AI tools in authoritative, peer-reviewed source material to ensure trust and accuracy at the point of care. [46, 47] It represents a key monetization strategy for scholarly publishers, who are licensing their extensive back-catalogs as essential 'gold in, gold out' training and retrieval data for the healthcare AI industry. [46]
Sources
- newsroom.wiley.com — https://newsroom.wiley.com/press-releases/press-release-details/2026/Wiley-and-OpenEvidence-Partner-to-Deliver-Trusted-Research-to-Physicians-at-the-Point-of-Care/default.aspx
- rdworldonline.com — https://www.rdworldonline.com/wiley-moves-deeper-into-clinical-ai-with-openevidence-content-licensing-pact/